Table 3

Patient and caregiver follow-up measures

MeasureBaseline (time point 0) mean score (SD) n=25Mean standardised effect size (d) from baseline
Time point 1
1–2 days post-IPOS (mean (Embedded Image , SD)) n=24
Time point 2
1–2 weeks post-IPOS (mean, SD) n=23
Time point 3
4–6 weeks post-IPOS (mean, SD) n=23
ESAS-r24.72 (16.73)0.05−0.31−0.11
(Embedded Image  23.9, SD 15.8)(Embedded Image  29.9, SD 19.6)(Embedded Image  26.5, SD 15.0)
KCCQ overall clinical summary score61.4 (25.4)0.18−0.23−0.02
(Embedded Image  62.6, SD 25.4)(Embedded Image  56.7, SD 17.2)(Embedded Image  59.8, SD 15.2)
KCCQ overall summary score56.6 (16.7)−0.06−0.09−0.02
(Embedded Image  56.3, SD 14.7)(Embedded Image  54.4, SD 15.3)(Embedded Image  55.6, SD 16.7)
KCCQ self-efficacy score82.1 (18.0)0.290.440.44
(Embedded Image  88.0, SD 11.6)(Embedded Image  89.7, SD 9.7)(Embedded Image  89.7, SD13.4)
PHQ-83.20 (4.21)0.010.100.10
Embedded Image  3.0, SD 3.6)(Embedded Image  2.8, SD 4.4)(Embedded Image  2.8, SD 3.9)
Quality of life (VAS)5.15 (1.25)0.220.160.34
(Embedded Image  5.5, SD 1.4)(Embedded Image  5.4, SD 1.4)(Embedded Image  5.6, SD 1.0)
ZBI-1221.90 (6.92)−0.56
(Embedded Image  25.8, SD 3.2)
  • ESAS, Edmonton symptom assessment system; IPOS, Integrated Palliative care Outcome Scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; PHQ-8: Patient-Health Questionnaire; VAS: Visual Analogue Scale; ZBI-12: Zarit Caregiver Burden Interview-12.